Corticosteroid, Platelet-Rich Plasma, and Ozone Injections for Sinus Tarsi Syndrome

Basit Öğe Kaydı
dc.contributor.authorToy, Serdar
dc.contributor.authorTuncer, Kutsi
dc.contributor.authorTopal, Murat
dc.contributor.authorAydın, Ali
dc.date.accessioned2023-03-16T08:01:45Z
dc.date.available2023-03-16T08:01:45Z
dc.date.issued2023en_US
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü,Ortopedi ve Travmatoloji Ana Bilim Dalıen_US
dc.description.abstractBackground: Sinus tarsi syndrome is characterized by permanent pain on the anterolateral side of the ankle due to chronic inflammation characterized by fibrotic tissue remnants and synovitis accumulation after repeated traumatic injuries. Few studies have documented the outcome of injection treatments for sinus tarsi syndrome. We sought to determine the effects of corticosteroid and local anesthetic (CLA), platelet-rich plasma (PRP), and ozone injections on sinus tarsi syndrome. Methods: Sixty patients with sinus tarsi syndrome were randomly divided into three treatment groups: CLA, PRP, and ozone injections. Outcome measures were visual analog scale, American Orthopedic Foot and Ankle Society Ankle-Hindfoot Scale (AOFAS), Foot Function Index, and Foot and Ankle Outcome Score before injection compared with 1, 3, and 6 months after injection. Results: At the end of months 1, 3, and 6 after injection, significant improvements were observed in all three groups compared with baseline (P < .001 for all). At months 1 and 3, improvements in AOFAS scores were similar in the CLA and ozone groups; those in the PRP group were lower (P = .001 and P = .004, respectively). At month 1, improvements in Foot and Ankle Outcome Score were similar in the PRP and ozone groups and higher in the CLA group (P < .001). At 6-month follow-up, there were no significant differences in visual analog scale and Foot Function Index results among the groups (P > .05). Conclusions: Ozone, CLA, or PRP injections could provide clinically significant functional improvement for at least 6 months in patients with sinus tarsi syndrome.en_US
dc.identifier.citationToy, S., Tuncer, K., Topal, M., & Aydın, A. (2023). Corticosteroid, Platelet-Rich Plasma, and Ozone Injections for Sinus Tarsi Syndrome. Journal of the American Podiatric Medical Association, 113(1).en_US
dc.identifier.issn8750-7315
dc.identifier.issn1930-8264
dc.identifier.issue1en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12939/3438
dc.identifier.volume113en_US
dc.identifier.wosWOS:001112027400018
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorTuncer, Kutsi
dc.language.isoen
dc.relation.ispartofJournal of the American Podiatric Medical Association
dc.relation.isversionof10.7547/20-221en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSinus Tarsi Syndromeen_US
dc.subjectPlatelet-Rich Plasma (PRP)en_US
dc.subjectLocal Anesthetic (CLA)en_US
dc.subjectOzoneen_US
dc.titleCorticosteroid, Platelet-Rich Plasma, and Ozone Injections for Sinus Tarsi Syndrome
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu